

# John S Schieffelin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/786002/publications.pdf>

Version: 2024-02-01

63  
papers

1,880  
citations

361045

20  
h-index

276539

41  
g-index

66  
all docs

66  
docs citations

66  
times ranked

2986  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. <i>Cell</i> , 2015, 162, 738-750.	13.5	230
2	Lassa Fever in Post-Conflict Sierra Leone. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2748.	1.3	172
3	Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. <i>Nature Communications</i> , 2016, 7, 11544.	5.8	148
4	Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in Adults With Suspected Infection in Low- and Middle-Income Countries. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2202.	3.8	147
5	Ebola virus disease and critical illness. <i>Critical Care</i> , 2016, 20, 217.	2.5	97
6	Using Modelling to Disentangle the Relative Contributions of Zoonotic and Anthroponotic Transmission: The Case of Lassa Fever. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e3398.	1.3	96
7	Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. <i>Virology Journal</i> , 2010, 7, 28.	1.4	87
8	Derivation and validation of a universal vital assessment (UVA) score: a tool for predicting mortality in adult hospitalised patients in sub-Saharan Africa. <i>BMJ Global Health</i> , 2017, 2, e000344.	2.0	58
9	Analysis of CD8 <sup>+</sup> T cell response during the 2013-2016 Ebola epidemic in West Africa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7578-E7586.	3.3	55
10	A Unified Framework for the Infection Dynamics of Zoonotic Spillover and Spread. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004957.	1.3	52
11	Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone. <i>EBioMedicine</i> , 2018, 30, 217-224.	2.7	42
12	Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. <i>Scientific Reports</i> , 2018, 8, 5939.	1.6	39
13	Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, S210-S217.	1.9	35
14	Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses. <i>Journal of Infectious Diseases</i> , 2020, 221, 156-161.	1.9	35
15	An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. <i>Journal of Infectious Diseases</i> , 2016, 214, S110-S121.	1.9	34
16	A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. <i>Immunity</i> , 2021, 54, 815-828.e5.	6.6	34
17	Multiple Circulating Infections Can Mimic the Early Stages of Viral Hemorrhagic Fevers and Possible Human Exposure to Filoviruses in Sierra Leone Prior to the 2014 Outbreak. <i>Viral Immunology</i> , 2015, 28, 19-31.	0.6	33
18	Congenital Cytomegalovirus Infection. <i>Ochsner Journal</i> , 2019, 19, 123-130.	0.5	32

#	ARTICLE	IF	CITATIONS
19	Development of Prototype Filovirus Recombinant Antigen Immunoassays. <i>Journal of Infectious Diseases</i> , 2015, 212, S359-S367.	1.9	30
20	Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, S203-S209.	1.9	29
21	Expanding Research Capacity in Sub-Saharan Africa Through Informatics, Bioinformatics, and Data Science Training Programs in Mali. <i>Frontiers in Genetics</i> , 2019, 10, 331.	1.1	26
22	A Review of Hearing Loss Associated with Zika, Ebola, and Lassa Fever. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 484-490.	0.6	24
23	Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans. <i>Viruses</i> , 2021, 13, 2325.	1.5	24
24	High crossreactivity of human T cell responses between Lassa virus lineages. <i>PLoS Pathogens</i> , 2020, 16, e1008352.	2.1	22
25	A tribute to Sheik Humarr Khan and all the healthcare workers in West Africa who have sacrificed in the fight against Ebola virus disease: Mae we hush. <i>Antiviral Research</i> , 2014, 111, 33-35.	1.9	19
26	Dengue and chikungunya seroprevalence among Qatari nationals and immigrants residing in Qatar. <i>PLoS ONE</i> , 2019, 14, e0211574.	1.1	19
27	What should define a SARS-CoV-2 "breakthrough" infection?. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	18
28	Ophthalmic manifestations and vision impairment in Lassa fever survivors. <i>PLoS ONE</i> , 2020, 15, e0243766.	1.1	17
29	Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. <i>Scientific Reports</i> , 2020, 10, 16030.	1.6	15
30	Identification of Common CD8 <sup>+</sup> T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone. <i>Journal of Virology</i> , 2020, 94, .	1.5	15
31	A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges. <i>PLoS ONE</i> , 2019, 14, e0214284.	1.1	14
32	Lassa Fever Induced Hearing Loss: The Neglected Disability of Hemorrhagic Fever. <i>International Journal of Infectious Diseases</i> , 2020, 100, 82-87.	1.5	14
33	Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. <i>Scientific Reports</i> , 2020, 10, 8724.	1.6	14
34	Ebola-Specific CD8 <sup>+</sup> and CD4 <sup>+</sup> T-Cell Responses in Sierra Leonean Ebola Virus Survivors With or Without Post-Ebola Sequelae. <i>Journal of Infectious Diseases</i> , 2020, 222, 1488-1497.	1.9	13
35	Clinical validation trial of a diagnostic for Ebola Zaire antigen detection: Design rationale and challenges to implementation. <i>Clinical Trials</i> , 2016, 13, 66-72.	0.7	12
36	Data set on Lassa fever in post-conflict Sierra Leone. <i>Data in Brief</i> , 2019, 23, 103673.	0.5	12

#	ARTICLE	IF	CITATIONS
37	Factors Associated with Mortality in Febrile Patients in a Government Referral Hospital in the Kenema District of Sierra Leone. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 172-177.	0.6	11
38	Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012–2019. <i>Microorganisms</i> , 2021, 9, 586.	1.6	10
39	Dengue fever: a new challenge for China?. <i>Global Health Action</i> , 2014, 7, 26421.	0.7	9
40	Hansen’s Disease and Rheumatoid Arthritis Crossover of Clinical Symptoms: A Case Series of 18 Patients in the United States. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1726-1730.	0.6	9
41	New-onset atrial arrhythmias associated with mortality in black and white patients hospitalized with COVID-19. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 856-864.	0.5	8
42	Health seeking behavior after the 2013–16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009576.	1.3	8
43	The Origins and Future of Sentinel: An Early-Warning System for Pandemic Preemption and Response. <i>Viruses</i> , 2021, 13, 1605.	1.5	8
44	Elevated l-threonine is a biomarker for Lassa fever and Ebola. <i>Virology Journal</i> , 2020, 17, 188.	1.4	7
45	Responses of three urban U.S. Children’s Hospitals to COVID-19: Seattle, New York and New Orleans. <i>Paediatric Respiratory Reviews</i> , 2020, 35, 15-19.	1.2	7
46	Raising the standard for clinical care of patients with Ebola virus disease. <i>Lancet Infectious Diseases</i> , 2015, 15, 1247-1248.	4.6	6
47	Implementation of the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) study: Lessons learned for vision health systems strengthening in Sierra Leone. <i>PLoS ONE</i> , 2021, 16, e0252905.	1.1	5
48	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
49	Treatment of Arenavirus Infections. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 261-270.	0.8	4
50	An effective and safe vaccine will not be enough to prepare us for the next Ebola outbreak. <i>Lancet Infectious Diseases</i> , 2017, 17, 1224-1225.	4.6	4
51	SARS-CoV-2 seroprevalence rates of children seeking medical care in Louisiana during the state stay at home order. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100047.	0.4	3
52	How natural disasters change natural patterns: coccidioidomycosis imported to New Orleans. <i>The Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society</i> , 2013, 165, 145-9.	0.1	3
53	Evaluation of Three Clinical Prediction Tools to Predict Mortality in Hospitalized Patients with Lassa Fever. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 107, 856-862.	0.6	3
54	Clinical features and viral RNA shedding of imported and local cases with COVID-19 in Wenzhou, China. <i>Medicine (United States)</i> , 2021, 100, e24826.	0.4	1

#	ARTICLE	IF	CITATIONS
55	Zika Virus Replication in a Mast Cell Model is Augmented by Dengue Virus Antibody-Dependent Enhancement and Features a Selective Immune Mediator Secretary Profile. Microbiology Spectrum, 0, , .	1.2	1
56	Infectious Disease Outbreaks: The Need For an All-in Approach. Journal of Infectious Diseases, 2020, 222, 1941-1942.	1.9	0
57	Boosting understanding of Lassa Fever virus epidemiology: Field testing a novel assay to identify past Lassa Fever virus infection in blood and oral fluids of survivors and unexposed controls in Sierra Leone. PLoS Neglected Tropical Diseases, 2021, 15, e0009255.	1.3	0
58	Does Screening Keep Ebola Out of USA?. Tropical Medicine & Surgery, 2014, 02, .	0.1	0
59	Emerging Trends in Clinical Tropical Medicine Research. American Journal of Tropical Medicine and Hygiene, 2019, 101, 8-11.	0.6	0
60	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
61	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
62	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
63	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0